Long-term follow-up is reinforcing durability expectations for neuromuscular gene therapy. A three-year phase 3 follow-up of EMBARK reported sustained functional benefits and slower disease progression for delandistrogene moxeparvovec in ambulatory patients with Duchenne muscular dystrophy. The update adds to the longitudinal evidence base needed for payers and clinicians weighing risk, durability, and real-world functional outcomes beyond initial trial milestones.
Get the Daily Brief